Log in  First Connection?

Acute & Chronic Kidney InjuryArchives

Comparison of SII, NLR, and SIRI for severity stratification and prognosis in sepsis-related acute kidney injury

 Published on 20/05/2026 |  Original article (Full-text)  | Zhihang Jiang et al. | Biomarkers in Medicine 2026; aop:10.1080/17520363.2026.2671012

Sepsis-associated acute kidney injury (SA-AKI) is a severe complication linked to excessive systemic inflammation and immune dysregulation, with high mortality and poor prognosis. To compare the predictive efficacy of the Systemic Immune-Inflammation Index (SII), Neutrophil-to-Lymphocyte Ratio (NLR),...

Predictors of acute kidney injury following the first cycle of high-dose methotrexate in patients with hematological malignancies

 Published on 13/05/2026 |  Original article (Full-text)  | Nour Faqeer et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2666843

Consensus regarding predictors of acute kidney injury (AKI) following high-dose methotrexate (HDMTX) across diverse patient populations remains inconsistent. We conducted a retrospective study to identify predictors of AKI in adult patients with hematological malignancies receiving the first cycle of...

Diagnosis, diagnostic approach and challenges in pregnancy-associated AKI-the ADQI 32 consensus meeting

 Published on 06/05/2026 |  Original article (Full-text)  | Nuttha Lumlertgul et al. | Nephrology Dialysis Transplantation. Volume 41(4).

Despite advancements in obstetric care, pregnancy-associated acute kidney injury (PrAKI) continues to be a significant public health concern, contributing to substantial maternal and fetal morbidity and mortality. The most common causes of PrAKI include preeclampsia/eclampsia, haemorrhage and infection....

Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI

 Published on 29/04/2026 |  Original article (Full-text)  | Phillip S Blanchette et al. | Nephrology Dialysis Transplantation. Volume 41(4).

Acute kidney injury (AKI) is a known immune-related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further population-based data on AKI incidence, risk factors and practice patterns post-ICI therapy are needed. Methods: We measured the cumulative incidence of AKI among advanced cancer...